Systemic bevacizumab treatment for recurrent respiratory papillomatosis: long‐term follow‐up

R Ruiz, N Balamuth, LR Javia, KB Zur - The Laryngoscope, 2022 - Wiley Online Library
Objectives/Hypothesis Systemic bevacizumab is a new adjuvant therapy for recurrent
respiratory papillomatosis (RRP) that has shown promising preliminary results in children …
被引用次数：20 相关文章

Systemic Bevacizumab Treatment for Recurrent Respiratory Papillomatosis: Long-Term Follow-Up.

R Ruiz, N Balamuth, LR Javia, KB Zur - The Laryngoscope, 2022 - europepmc.org
Methods Retrospective review of seven pediatric patients treated within the past 6 years with
systemic bevacizumab for RRP refractory to traditional debridement. Results All seven …

Systemic Bevacizumab Treatment for Recurrent Respiratory Papillomatosis: Long-Term Follow-Up

R Ruiz, N Balamuth, LR Javia… - The Laryngoscope, 2022 - pubmed.ncbi.nlm.nih.gov
Objectives/hypothesis Systemic bevacizumab is a new adjuvant therapy for recurrent
respiratory papillomatosis (RRP) that has shown promising preliminary results in children …

Systemic Bevacizumab Treatment for Recurrent Respiratory Papillomatosis: Long‐Term Follow‐Up.

R Ruiz, N Balamuth, LR Javia, KB Zur - Laryngoscope, 2022 - search.ebscohost.com
Abstract Objectives/Hypothesis: Systemic bevacizumab is a new adjuvant therapy for
recurrent respiratory papillomatosis (RRP) that has shown promising preliminary results in …